Dallas, TX, United States of America

John Russell Falck

USPTO Granted Patents = 34 

 

 

Average Co-Inventor Count = 3.2

ph-index = 6

Forward Citations = 133(Granted Patents)


Location History:

  • Dallas, TX (US) (1994 - 2022)
  • University Park, TX (US) (1998 - 2022)
  • Austin, TX (US) (2023)
  • University Park, CA (US) (2024)

Company Filing History:

goldMedal19 out of 5,450 
 
The University of Texas System
 patents
silverMedal4 out of 4 
 
Cytometix, Inc.
 patents
bronzeMedal3 out of 61 
 
Mcw Research Foundation, Inc.
 patents
43 out of 18 
 
Max-delbrueck-centrum Fuer Molekulare Medizin
 patents
53 out of 182 
 
The Medical College of Wisconsin, Inc.
 patents
63 out of 41 
 
New York Medical College
 patents
72 out of 49 
 
Medical College of Georgia Research Institute, Inc.
 patents
82 out of 204 
 
University of Vermont and State Agricultural College
 patents
91 out of 43 
 
University of Vermont
 patents
101 out of 2 
 
Max-delbrueck-centrum Fuer Molekulare Medizin (mdc)
 patents
111 out of 1 
 
Omm Scientific Inc.
 patent
121 out of 30 
 
Max-delbruck-centrum Fur Molekulare Medizin
 patents
131 out of 2 
 
Omeicos Therapeutics Gmbh
 patents
141 out of 71 
 
Alcon Universal Ltd.
 patents
151 out of 313 
 
Oregon State University
 patents
161 out of 633 
 
William Marsh Rice University
 patents
171 out of 1,177 
 
Alcon, Inc.
 patents
183 out of 832,843 
Other
 patents
where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...
Loading Chart...
Loading Chart...
34 patents (USPTO):Explore Patents

Title: Innovations and Contributions of John Russell Falck in the Field of Therapeutics

Introduction: John Russell Falck, an accomplished inventor based in Dallas, TX, has made significant contributions to the field of therapeutics with a remarkable portfolio of 34 patents. His work primarily focuses on the development and therapeutic delivery of innovative compounds aimed at addressing various health conditions.

Latest Patents: Among his latest patents are groundbreaking methods surrounding 14,15-epoxyeicosatrienoic acid analogs and improved therapeutic delivery systems. These inventions highlight novel systems, compositions, and methodologies designed to develop and effectively deliver therapeutically beneficial 14,15-EET analogs for pain management and treatment. Another notable patent encompasses the discovery of 20-HETE receptor (GPR75) antagonists and their applications in treating a range of diseases, including cardiovascular and renal diseases, thrombic disease, stroke, metabolic syndrome, and ischemic cardiovascular disorders. These compounds exhibit significant potency, functioning as anti-hypertensive, anti-inflammatory, and anti-growth agents.

Career Highlights: John Russell Falck has had a distinguished career, working with prestigious organizations, including the University of Texas System and Cytometix, Inc. His innovative approach and in-depth understanding of biochemical processes have positioned him as a leading figure in his field.

Collaborations: Throughout his career, Falck has collaborated with esteemed colleagues such as John David Imig and Martin M Bednar. These partnerships have undoubtedly facilitated the advancement of his research and have contributed to the successful development of his patented technologies.

Conclusion: John Russell Falck stands out as a significant innovator in the therapeutic space, with a strong focus on addressing critical health challenges through his patented inventions. His work continues to influence the field, paving the way for new treatments and therapies that enhance patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…